Emerging Concepts In Treating Onychomycosis
- Volume 22 - Issue 10 - October 2009
- 35305 reads
- 1 comments
A Guide To Current And Emerging Topical Treatments
In the early 1990s, the Food and Drug Administration (FDA) stated that no topical remedy could claim efficacy against onychomycosis. Currently, only ciclopirox lacquer (Penlac, Sanofi Aventis) is approved for mild to moderate onychomycosis of the fingers or toenails.
Ciclopirox is a hydroxypyridone with a unique mechanism of action. It works by chelating the polyvalent cations (Fe+3 or Al+3), resulting in the inhibition of metal dependent enzymes that degrade the toxic peroxides within the fungal cell. Mycological cure rates have been good but clinical cure rates are approximately one-quarter that of oral medications.9
Other medications that have shown anecdotal success are tea tree oil, Vicks Vapor rub, Listerine and oral medications dissolved in different mediums including dimethyl sulfoxide (DMSO). None of these have FDA approval or are substantiated by evidence-based medicine.9-11
In regard to new topical agents, Schering Plough has acquired AN2690, a new topical antifungal that targets fungal protein synthesis. An essential enzyme in fungal synthesis is leucyl-transfer RNA synthetase (LeuRS). AN2690 inhibits protein synthesis by denaturing LeurRS, which leads to the termination of cell growth or cell death.12 This inhibition requires a boron molecule to be replaced with a carbon molecule. In theory, this will eliminate fungal infection.
When it comes to possible side effects for AN2690, initial phase II trials led to little or no detectable drug exposure in urine or blood, negating possible systemic issues. The main side effect was mild to moderate local skin reaction. Schering-Plough will begin phase III clinical trials in 2009. The company claims that this new topical treatment will be 250 times more powerful than Penlac, the only currently approved topical therapy for onychomycosis in the U.S.12
Another way to improve topical medications is to improve transport technology. Current work is centering on an iontophoretic control device that delivers an electrical current with a dose of terbinafine (Lamisil, Novartis) to the nail bed by electrode. The goal is to drive the drug through the nail as well as saturate the nail and nail bed. This will create a reservoir of antifungal medication, which will allow continual release of terbinafine to the underside of the nail where onychomycosis develops.
The same features that make drug delivery to the nail difficult (i.e. a lack of blood vessels and a waxy, impermeable surface) improve the half-life of drugs that do penetrate. Also bear in mind that the structure of the nail creates an excellent reservoir for holding drugs and releasing them over time. This will help eliminate high systemic concentrations and drug interaction concerns.
A double-blind, randomized pilot study of 28 patients using iontophoresis with terbinafine hydrochloride showed a 64 percent clinical improvement in comparison to the placebo group at week 24. Final data is not available at this time.13
NanoBio Corporation is developing NB-002, a new topical treatment for onchomycosis. This oil-in-water emulsion is currently in phase II development. With this treatment, high-energy nano-sized particles penetrate the skin pores and diffuse through the skin that surrounds the entire nail plate, according to a study by NanoBio Corporation.14 Upon contact with the pathogen, the highly charged particles release their energies to the pathogen’s outer membranes, disrupting the fungus.
NanoBio states that NB-002 is able to achieve 50 times the minimum drug concentration needed to kill the fungus in the center of the nail bed. Studies conducted in vitro demonstrate that NB-002 has antifungal activity against the organisms (including T. rubrum, T. mentagrophytes, Epidermophyton floccosum and Candida albicans) that cause nail fungus.14